Boston, MA, 11/14/2013 (nysepost) – In Wednesday’s trading session, Oxygen Biotherapeutics, Inc (NASDAQ:OXBT) dropped by 8.57%. The shares opened at a price of $6.81, which touched the intraday high of $6.90 and headed to a close of $6.40. Around 1.60 million exchanged hands over the trading day and an average volume of 5.34 million shares were traded over a 30 day period. The 52-week low of Oxygen Biotherapeutics, Inc (NASDAQ:OXBT) shares is $1.19 and its 52-week high is $20.00. The company has a market capitalization of $32.33 billion.
About the company
Oxygen Biotherapeutics, Inc (NASDAQ:OXBT) is involved in developing bio-technology products that have a primary focus on oxygen-delivery to tissue. As of 30 April 30, it is developing Oxycyte. This is a systemic-perfluorcarbon product. It has developed a huge family of perfluorocarbon-based-oxygen carriers that are to be used in personal care, topical-wound healing as well as other topical indications. In addition to this, Oxygen Biotherapeutics, Inc (NASDAQ:OXBT) has under its development Vitavent. This an oxygen-exchange fluid that is used for facilitating treatment of various lung conditions & it has out licensed the rights to its biosensor-implant product that utilizes an enzyme-process for measurement of glucose level in the subcutaneous fluid.
The future of medical marijuana is all about the delivery system. MediJane brings you transdermal patches, Gel Capsules, Sublingual's and topical creams. Learn more about MediJane Holdings, Inc. (OTCQB: MJMD) Click Here Now
Oxygen Biotherapeutics, Inc (NASDAQ:OXBT)’s Oxycyte oxygen carrier product is a PFC- based oil-in water emulsion. This product is given to the patient intravenously. The physical-properties of PFC allow its product to gather the oxygen from lungs and transport this oxygen through the entire body releasing it as it moves along. Over a period of few days Oxycyte slowly evaporates inside the lungs from where it is later exhaled. Oxycyte is provided as this sterile emulsion that ready for intravenous-administration.
Oxygen Biotherapeutics, Inc (NASDAQ:OXBT)’s Dermacyte line of topical-cosmetic products employ its PFC technology & other known cosmetic -ingredients to promote appearance of skin-health and other desirable-cosmetic benefits.